Induction of interleukin-6 production by rituximab in human B cells

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 2938-2946

  Jones, Jonathan D ^a   Hamilton, B Jonell ^b   Skopelja, Sladjana ^b   Rigby, William F C ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CD19 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN D; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE FUNCTION AND CHARACTERISTICS; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TROGOCYTOSIS; UPREGULATION; CELL CULTURE; DRUG EFFECTS; METABOLISM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD40; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN D; IN VITRO TECHNIQUES; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-4; INTERLEUKIN-6; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84925582273     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38798     Document Type: Article

References (39)

1. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ,. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26 Suppl 14: 79-87.
2. McLaughlin P,. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol 2001; 40: 3-16.
3. Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR, Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 2007; 33: 161-76.
4. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR,. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25.
5. Glennie MJ, French RR, Cragg MS, Taylor RP,. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-37.
6. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al., Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al., The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
8. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
9. Martin F, Chan AC,. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-96.
10. Fillatreau S,. Cytokine-producing B cells as regulators of pathogenic and protective immune responses. Ann Rheum Dis 2013; 72 Suppl 2: ii80-4.
11. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al., Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-9.
12. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al., B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209: 1001-10.
13. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP,. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176: 2600-9.
14. Jones JD, Hamilton BJ, Rigby WF,. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum 2012; 64: 3111-8.
15. Arnold PY, Davidian DK, Mannie MD,. Antigen presentation by T cells: T cell receptor ligation promotes antigen acquisition from professional antigen-presenting cells. Eur J Immunol 1997; 27: 3198-205.
16. Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E,. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol 2001; 166: 3645-9.
17. Batista FD, Iber D, Neuberger MS,. B cells acquire antigen from target cells after synapse formation. Nature 2001; 411: 489-94.
18. Pham T, Mero P, Booth JW,. Dynamics of macrophage trogocytosis of rituximab-coated B cells. PLoS One 2011; 6: e14498.
19. Pedersen AE, Jungersen MB, Pedersen CD,. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology 2011; 133: 239-45.
20. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH,. Trogocytosis of multiple B-cell surface markers by CD22-targeting with epratuzumab. Blood 2013; 122: 3020-9.
21. Zhang Y, McClellan M, Efros L, Shi D, Bielekova B, Tang M, et al., Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis. Mult Scler 2014; 20: 156-64.
22. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP,. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181: 8120-32.
23. Van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, et al., An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354: 1901-12.
24. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al., CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120: 214-22.
25. Gough NM,. Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells. Anal Biochem 1988; 173: 93-5.
26. Garcia-Vallejo JJ, Van Het Hof B, Robben J, Van Wijk JA, Van Die I, Joziasse DH, et al., Approach for defining endogenous reference genes in gene expression experiments. Anal Biochem 2004; 329: 293-9.
27. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W, et al., IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 2003; 171: 4830-6.
28. Manderson AP, Kay JG, Hammond LA, Brown DL, Stow JL,. Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFα. J Cell Biol 2007; 178: 57-69.
29. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ,. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-74.
30. Deans JP, Robbins SM, Polyak MJ, Savage JA,. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273: 344-8.
31. Li H, Ayer LM, Lytton J, Deans JP,. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003; 278: 42427-34.
32. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, et al., Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008; 283: 16971-84.
33. Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP,. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007; 179: 4263-71.
34. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, et al., Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-8.
35. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al., Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177: 7435-43.
36. Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, et al., Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 2011; 187: 3438-47.
37. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD,. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004; 4: 1357-60.
38. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, et al., Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177: 7435-43.
39. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A,. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-24.